लोड हो रहा है...
Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial
Recurrence rate of hepatocellular carcinoma (HCC) is very high even after curative surgery, and no postoperative therapies have been definitively shown to prevent HCC recurrence. Sorafenib is proved to be effective for advanced HCC by two large randomized controlled trials in 2008 and 2009. Therefor...
में बचाया:
| में प्रकाशित: | World J Hepatol |
|---|---|
| मुख्य लेखकों: | , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Baishideng Publishing Group Inc
2016
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4990759/ https://ncbi.nlm.nih.gov/pubmed/27621761 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v8.i23.957 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|